Didier Borderie

Didier Borderie

Auto-generated profile, based on publicly available information

Didier Borderie

Laboratoire de Biochimie A, Hôpital Cochin, Paris, France

Research Focus & Metrics

Representative Publications

View All Publications
1 October 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
CCCamille Chenevier-Gobeaux
Camille Chenevier-Gobeaux
DBDidier Borderie
Didier Borderie
NWNicolas Weiss
Nicolas Weiss
TMThomas Mallet-Coste
Thomas Mallet-Coste
YCYann-Erick Claessens
Yann-Erick Claessens

1 February 2016 in Biochimie
Verified
Journal Article
Closed access
SCS. Le Clanche
S. Le Clanche
BRBonnefont Rousselot
Bonnefont Rousselot
ESE. Sari-Ali
E. Sari-Ali
FRF. Rannou
F. Rannou
DBD. Borderie
D. Borderie

22 June 2012 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
CACecile Aubron
Cecile Aubron
JGJeremy Glodt
Jeremy Glodt
CMCorine Matar
Corine Matar
OHOlivier Huet
Olivier Huet
DBDidier Borderie
Didier Borderie
OBOdile Bouvet
Odile Bouvet
Background: Uropathogenic strains of Escherichia coli cause symptomatic infections whereas asymptomatic bacteriuria (ABU) strains are well adapted for growth in the human urinary tract, where they establish long-term bacteriuria. Human urine is a very complex growth medium that could be perceived by certain bacteria as a stressful environment. To investigate a possible imbalance between endogenous oxidative response and antioxidant mechanisms, lipid oxidative damage estimated as thiobarbituric acid reactive substances (TBARS) content was evaluated in twenty-one E. coli belonging to various pathovars and phylogenetic groups. Antioxidant defense mechanisms were also analysed. Results: During exponential growth in urine, TBARS level differs between strains, without correlation with the ability to grow in urine which was similarly limited for commensal, ABU and uropathogenic strains. In addition, no correlation between TBARS level and the phylogroup or pathogenic group is apparent. The growth of ABU strain 83972 was associated with a high level of TBARS and more active antioxidant defenses that reduce the imbalance. Conclusions: Our results indicate that growth capacity in urine is not a property of ABU strains. However, E. coli isolates respond very differently to this stressful environment. In strain ABU 83972, on one hand, the increased level of endogenous reactive oxygen species may be responsible for adaptive mutations. On the other hand, a more active antioxidant defense system could increase the capacity to colonize the bladder.

29 November 2012 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
CACecile Aubron
Cecile Aubron
OHOlivier Huet
Olivier Huet
SRSylvie Ricome
Sylvie Ricome
DBDidier Borderie
Didier Borderie
EPEric Pussard
Eric Pussard
JDJacques Duranteau
Jacques Duranteau
Critically ill patients including trauma patients are at high risk of urinary tract infection (UTI). The composition of urine in trauma patients may be modified due to inflammation, systemic stress, rhabdomyolysis, life support treatment and/or urinary catheter insertion.

1 October 2001 in Life Sciences
Verified
Journal Article
Closed access
LCLeonor Correia
Leonor Correia
PPPhilippe Podevin
Philippe Podevin
DBDidier Borderie
Didier Borderie
NVNicole Verthier
Nicole Verthier
JMJean-Claude Montet
Jean-Claude Montet
YCYvon Calmus
Yvon Calmus

29 January 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
Nicolas MongardonNicolas Mongardon
Nicolas Mongardon
VLVirginie Lemiale
Virginie Lemiale
DBDidier Borderie
Didier Borderie
ABAnne Burke-Gaffney
Anne Burke-Gaffney
SPSébastien Perbet
Sébastien Perbet
ACAlain Cariou
Alain Cariou
Introduction: Despite experimental evidence, clinical demonstration of acute state of oxidative stress and inflammation during post-cardiac arrest syndrome is lacking. Plasma level of thioredoxin (TRX), a redox-active protein induced under conditions of oxidative stress and inflammation, is increased in various critical care conditions. We determined plasma TRX concentrations after cardiac arrest and assessed relationships with severity and outcome. Methods: Retrospective study of consecutive patients admitted to a single academic intensive care unit (ICU) for out-of-hospital cardiac arrest (between July 2006 and March 2008). Plasma levels of TRX were measured at admission, day (D) 1, 2 and 3. Results: Of 176 patients included, median TRX values measured in ICU survivors and non-survivors were, respectively: 22 ng/mL (7.8 to 77) vs. 72.4 (21.9 to 117.9) at admission (P < 0.001); 5.9 (3.5 to 25.5) vs. 23.2 (5.8 to 81.4) at D1 (P = 0.003); 10.8 (3.6 to 50.8) vs. 11.7 (4.5 to 66.4) at D2 (P = 0.22); and 16.7 (5.3 to 68.3) vs. 17 (4.3 to 62.9) at D3 (P = 0.96). Patients dying within 24 hours had significantly (P < 0.001) higher TRX levels (118.6 ng/mL (94.8 to 280)) than those who died after 24 hours or survived (50.8 (13.9 to 95.7) and 22 (7.8 to 77)). The area under the ROC curve to predict early death was 0.84 (0.76 to 0.91). TRX levels on admission were significantly correlated with 'low-flow' duration (P = 0.003), sequential organ failure assessment (SOFA) score (P < 0.001), and blood lactate concentration (P < 0.001), but not with 'no-flow' duration or simplified acute physiology score (SAPS) II score. TRX levels and admission arterial pO2 correlated negatively (r = -0.17, P = 0.03). Finally, cardiac arrest with cardiac etiology exhibited lower levels of TRX than in cases of extra-cardiac cause (46 ng/mL (11 to 104) vs. 68 (42 to 137), P = 0.01). Conclusions: Our data show for the first time that TRX levels were elevated early following cardiac arrest, suggestive of oxidative stress and inflammation occurring with this condition. Highest values were found in the most severe patients. TRX could be a useful tool for further exploration and comprehension of post-cardiac arrest syndrome.